Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)

Affiliations

• ¹ Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne, Victoria, Australia; Department of Clinical Haematology, Monash University, Clayton, Victoria.
• ² Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne, Victoria.
• ³ Royal Prince Alfred Hospital, Sydney.
• ⁴ Princess Alexandra Hospital and University of Queensland, Brisbane.
• ⁵ The Canberra Hospital, Canberra.
• ⁶ Icon Cancer Centre, Brisbane.
• ⁷ Concord Repatriation General Hospital, University of Sydney, Sydney.
• ⁸ Nanix Ltd., Dunedin, New Zealand; Department of Microbiology and Immunology, University of Otago.
• ⁹ Department of Microbiology and Immunology, University of Otago.
• ¹⁰ Materials Characterisation and Fabrication Platform, Department of Chemical Engineering, University of Melbourne.
• ¹¹ Department of Epidemiology and Preventive Medicine, Alfred Health - Monash University, Melbourne, Victoria.
• ¹² Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria.
• ¹³ Faculty of Medicine, University of Melbourne, St Vincent's Hospital Melbourne, Australia [on behalf of The Australasian Leukaemia and Lymphoma Group (ALLG)].
• ¹⁴ Malignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne, Victoria, Australia; Department of Clinical Haematology, Monash University, Clayton, Victoria. Andrew.spencer@monash.edu.